Welcome to the ‘Ideas to Innovation’ podcast series. In this new series, we engage in conversation with experts and industry leaders to discuss innovation at its core. Learn more about the new series.
On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer’s treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the buildup of a protein known as beta amyloid that some think might be a possible cause of Alzheimer’s disease. While the approval has been applauded by some, it is not without controversy. In this session, we ask our guests how innovation in the search for treatments of Alzheimer’s disease is evolving.
Our guest speakers include:
- Mei Mei Hu, Chief Executive Officer at Vaxxinity;
- Hans J. Moebius, Chief Medical Officer at Athira Pharma;
- Raymond J Tesi, Chief Executive Officer and Chief Medical Officer at Inmune Bio;
- Jerre Stead, Executive Chairman and Chief Executive Officer of Clarivate; and
- Jonathan Searles, Senior Director on the CNS/Ophthalmology therapy team at Clarivate.
Listen to the conversation now:
